BioCentury

8:00 AM GMT, Feb 2, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Esperance: Harmonizing hormones to cancer

Based on a technology invented at Louisiana State University as a means of sterilizing animals, Esperance Pharmaceuticals Inc. is developing fusion proteins that combine a tumor-seeking hormone receptor ligand and a cytotoxin to treat cancer. Next quarter, the company plans to start a Phase I trial of EP-100, which incorporates a cytotoxic peptide that may avoid resistance mechanisms because it causes tumor cell death without needing to be internalized.

"The

Read the full 694 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.